title: A 31-phosphorus neurospectroscopy study of omega-3 long-chain polyunsaturated fatty acid intervention with eicosapentaenoic acid and docosahexaenoic acid in patients with chronic refractory epilepsy.
abstract: The aim of this study was to determine whether supplementation with the n-3 long-chain polyunsaturated fatty acids eicosapentaenoic acid and docosahexaenoic acid in patients with chronic refractory epilepsy is associated with beneficial changes in cerebral biochemistry. In a 3-month pilot randomized double-blind placebo-controlled study, three patients received eicosapentaenoic acid and docosahexaenoic acid daily and four received a placebo. 31-Phosphorus neurospectroscopy showed a decrease in phosphodiesters, an increase in gammaNTP and an increase in the broadband component in the active group over this period, while the opposite changes occurred in the placebo group. Therefore, in chronic refractory epilepsy, omega-3 supplementation may be associated with reduced membrane phospholipid breakdown in the brain, an improvement in brain energy metabolism, and an increased level of phospholipids in membranes and/or vesicle bilayers in cells in the brain. The unfavourable biochemical changes observed in the placebo group may be a feature of chronic intractable epilepsy.
authors.affiliation: MRI Unit, Imaging Sciences Department, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Hospital, London, UK. basant.puri@csc.mrc.ac.uk
authors.forename: B K
authors.initials: BK
authors.lastname: Puri
authors.forename: M J
authors.initials: MJ
authors.lastname: Koepp
authors.forename: J
authors.initials: J
authors.lastname: Holmes
authors.forename: G
authors.initials: G
authors.lastname: Hamilton
authors.forename: A W C
authors.initials: AW
authors.lastname: Yuen
mesh_terms: D000328:Adult; D000368:Aged; D001921:Brain / Q000033:anatomy & histology / Q000378:metabolism*; D004281:Docosahexaenoic Acids / Q000378:metabolism / Q000627:therapeutic use; D015118:Eicosapentaenoic Acid / Q000378:metabolism / Q000627:therapeutic use; D004827:Epilepsy / Q000188:drug therapy*; D015525:Fatty Acids, Omega-3 / Q000378:metabolism / Q000627:therapeutic use; D006801:Humans; D009682:Magnetic Resonance Spectroscopy; D008875:Middle Aged; D010865:Pilot Projects; D010919:Placebos
chemical_list: D015525:Fatty Acids, Omega-3; D010919:Placebos; D004281:Docosahexaenoic Acids; D015118:Eicosapentaenoic Acid